Paul Thomas

Nov 10, 2024 | nature.com | Jordan Douglas |Jing L. Wang |Joep de Ligt |Paul Thomas |Richard Webby |Nigel French | +2 more

AbstractHuman respiratory syncytial virus (RSV) is a major cause of acute respiratory infection. In 2020, RSV was eliminated from New Zealand due to non-pharmaceutical interventions (NPI) used to control the spread of SARS-CoV-2. However, in 2021, following a brief quarantine-free travel agreement with Australia, there was a large-scale nationwide outbreak of RSV that led to reported cases more than five-times higher than typical seasonal patterns.

Nov 8, 2023 | nature.com | Caleb A Lareau |Yajie Yin |Katie Maurer |Katalin Sandor |Bence Daniel |Jose Sanz Peña | +20 more

AbstractCell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated human cells are understudied. For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)1.

Mar 26, 2023 | cell.com | Jingyou Yu |Paul Thomas |Michaela Sciacca

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown.